NBSE
NeuBase Therapeutics, Inc. Common Stock
NBSE
NBSE
Delisted
NBSE was delisted on the 10th of May, 2024.
45 hedge funds and large institutions have $23.3M invested in NeuBase Therapeutics, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 12 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
45
Holders Change
–
Holders Change %
0%
% of All Funds
0.71%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
6
Increased
8
Reduced
12
Closed
6
Calls
$56K
Puts
$15K
Net Calls
+$41K
Net Calls Change
+$80K
Top Buyers
1 |
CM
CM Management
Gulf Breeze,
Florida
|
+$329K |
2 |
Renaissance Technologies
New York
|
+$174K |
3 |
WPW
Waldron Private Wealth
Bridgeville,
Pennsylvania
|
+$111K |
4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$84.1K |
5 |
D.E. Shaw & Co
New York
|
+$70K |
Top Sellers
1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$574K |
2 |
Citadel Advisors
Miami,
Florida
|
-$83K |
3 |
FLC
Fifth Lane Capital
Austin,
Texas
|
-$56K |
4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$28.2K |
5 |
Two Sigma Advisers
New York
|
-$27.9K |